Mobile

HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT)

Update Il y a 4 ans
Reference: EUCTR2009-018123-32

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

• To evaluate the long-term safety of dimebon (latrepirdine) in Huntington disease (HD) subjects who have successfully completed 26 weeks of blinded treatment in the HORIZON protocol (DIM20).

Inclusion criteria

  • Huntington`s Corea

Links